Pharmacological studies with lincomycin in late pregnancy

Area of Science:

• Pharmacology
• Obstetrics
• Maternal-Fetal Medicine

Background:

• Lincomycin is an antibiotic used during pregnancy.
• Understanding its placental transfer is crucial for maternal and fetal safety.

Purpose of the Study:

• To investigate the placental transmission and pharmacokinetic profile of lincomycin in late pregnancy.
• To assess lincomycin levels in maternal blood, cord blood, and amniotic fluid.

Main Methods:

• Studied 60 pregnant patients in late pregnancy receiving lincomycin.
• Measured maternal blood, cord blood, and amniotic fluid lincomycin concentrations over time.
• Monitored for adverse effects in mothers and infants.

Main Results:

• Peak maternal lincomycin levels reached 12.5 mug/ml, with detectable levels up to 42 hours.
• Peak cord blood levels were 2.7 mug/ml, approximately one-quarter of maternal levels, with levels undetectable after 24 hours in most cases.
• Amniotic fluid lincomycin levels were variable but consistently higher than maternal or cord blood levels, persisting up to 52 hours.
• No significant accumulation occurred with repeated injections.
• One potential case of maternal neuromuscular block was noted; no infant adverse effects were observed.

Conclusions:

• Lincomycin demonstrates transplacental passage, with lower concentrations in cord blood compared to maternal blood.
• Amniotic fluid serves as a reservoir for lincomycin, with prolonged detectable levels.
• The study suggests a generally safe profile for lincomycin use in late pregnancy regarding fetal exposure and accumulation.